CJC-1295 with DAC: Identity, Albumin Binding, and Evidence Attribution

The clearest evidence-based answer is limited: CJC-1295 with DAC research concerns a long-acting growth hormone-releasing hormone (GHRH) analog described in the early human literature as binding endogenous albumin. Those studies measured growth hormone (GH), insulin-like growth factor I (IGF-I), and related research endpoints. They did not establish that a catalog item bearing a similar name is analytically identical to the studied material.

The distinction matters when comparing with-DAC and without-DAC listings. A product name identifies a catalog entry; it does not establish molecular identity, batch composition, clinical benefit, or permission to transfer findings between entries. The studies cited here support a careful reading of the studied analog, not an assumption of product equivalence.

Research boundary: This article is for research education only. It describes published observations and catalog terminology, not instructions for human or veterinary use. Historical study findings should not be read as preparation, administration, treatment, efficacy, or safety guidance for a research material.

What is CJC-1295 with DAC?

GHRH analog terminology

GHRH stands for growth hormone-releasing hormone. In the studies discussed here, CJC-1295 is described as a synthetic, long-acting GHRH analog. The description identifies the research pathway under investigation: researchers examined changes in GH secretion and in IGF-I, a related measured hormone endpoint. It does not describe every material that might be sold under a similar name.

The phrase CJC-1295 with DAC combines a compound name with terminology for a drug affinity complex design. In this context, DAC matters because the published long-acting analog is described as associating with endogenous albumin. That molecular feature is relevant to interpreting the duration reported in the human studies. It should not be treated as something proven about an individual catalog batch merely because the words appear on a listing.

The distinction between a pathway and a product also matters. A study can establish what happened to specified measurements in its participants under its research conditions. It cannot, by its title alone, establish the analytical identity of a separately listed research material. That is the central evidence boundary for CJC-1295 with DAC research.

Albumin binding and long-acting design

Albumin is a protein present in blood. The published description of the studied analog says it binds endogenous albumin, helping explain its extended presence in circulation. Across the two 2006 human studies, the reported half-life was approximately six to eight days. Half-life is a pharmacokinetic description of how a measured concentration changes over time; it is not a suggested use interval for a catalog product.

The pulsatility study describes binding to endogenous albumin in its account of the long-acting analog. A separate 2019 paper reports an LC-MS/MS method for confirming CJC-1295 in equine plasma. That paper belongs to an analytical detection context, not a human outcome context. It helps illustrate why confirmation is a laboratory question; it does not confirm the identity of BioPharma stock or extend the human findings to another species.

Albumin binding is therefore useful for explaining the studied design, but it cannot close an identity gap. Before attributing a published duration or hormone response to any other material, a reader must distinguish what the paper says about its study material from what independent documentation establishes about the material being considered.

Why with-DAC and without-DAC names need careful interpretation

Catalog names versus analytical identity

BioPharma lists separate items named CJC-1295 with DAC 5mg and CJC-1295 without DAC 5mg. These are catalog facts: two names and their listed quantities. The entries alone do not verify a batch’s molecular identity, purity, composition, or equivalence to material used in a published trial. In particular, the without-DAC name should not be expanded into an assumed sequence or assigned the properties of the long-acting analog without evidence specific to that material.

A useful reading habit is to ask what each statement actually documents. “With DAC” on a page is a label. “Binds endogenous albumin” is a description of the analog in the cited research. A measured result in healthy volunteers belongs to the material and conditions of that study. None of these statements, by itself, is a laboratory confirmation of a current catalog batch.

The listed quantity is subject to the same boundary. It describes how an item appears in a catalog, not the tested amount in a human study or an instruction for any use. Comparing listings by name and quantity can help a purchaser identify which entry they are reviewing, but cannot resolve whether either entry matches a published study material.

What must be matched before transferring study findings

Evidence attribution requires more than a shared name. The relevant questions include whether the documented molecular form matches the studied analog, whether the DAC-related feature is supported for the material at issue, and whether batch-level analytical documentation supports the claimed identity. Study population, measurement, and observation period also matter: a finding about GH or IGF-I in healthy adults remains a finding about those endpoints in that research setting.

Even a well-documented molecular match would not turn a hormone measurement into an unmeasured clinical outcome. Conversely, a label difference is reason to pause before applying a long-acting finding to a without-DAC listing; it is not a substitute for analytical characterization of either item. The evidence available here does not include a head-to-head human comparison establishing that the two catalog entries behave alike or differently.

This is an evidence-attribution inference, not a new experimental finding: when a paper studies a specified long-acting analog, its results cannot automatically be assigned to a separately named commercial material. Keeping that inference explicit prevents both overclaiming and the equally unsupported assumption that a catalog label supplies complete chemical documentation.

What the early human studies measured

Randomized trials: hormone and pharmacokinetic endpoints

Teichman and colleagues reported two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21–61. The trials lasted 28 and 49 days. Their principal measurements included GH and IGF-I concentrations and standard pharmacokinetic parameters for CJC-1295. This is evidence about measured hormone responses and the studied compound’s observed time course, not a demonstration of a consumer benefit.

Following single administration in the trials, mean GH increased by a reported two- to tenfold for at least six days, while mean IGF-I increased by 1.5- to threefold for nine to eleven days. The estimated half-life was 5.8–8.1 days. Following multiple administrations within the research trials, mean IGF-I remained above baseline for up to 28 days. These figures describe historical observations; they are neither a schedule nor evidence that a catalog listing will reproduce them.

The authors reported no serious adverse reactions in those trials. That is a statement about what was reported in the studied participants over the trial periods. It does not establish long-term safety, characterize an independently listed batch, or justify human use of research material. Although the paper discussed potential therapeutic utility, the endpoints summarized here remain distinct from demonstrated treatment outcomes.

Pulsatility research

Ionescu and Frohman asked a narrower physiological question: would GH secretion remain pulsatile during the sustained stimulation associated with the studied analog? They assessed GH using blood samples collected at 20-minute intervals overnight in healthy men aged 20–40. That sampling detail describes how researchers measured a pattern; it is not a protocol for using the compound.

The study reported that GH pulses were preserved. Pulse frequency and magnitude were unaltered, while trough GH—the lower measured GH level between peaks—rose by approximately 7.5-fold. Mean GH rose by 46%, and IGF-I by 45%. The investigators also reported that the IGF-I increases did not correlate with the GH secretion parameters they evaluated.

These observations refine the interpretation of “increased GH.” A higher mean value need not mean that each pulse grew larger or became more frequent; a raised trough can contribute to the change. That distinction helps readers understand the reported physiology without turning a measured pattern into a claim about benefit, performance, or the behavior of an unverified catalog material.

Exploratory serum-protein biomarkers

A 2009 study by Sackmann-Sala and colleagues looked beyond GH and IGF-I concentrations. Researchers compared sera from 11 healthy young adult men before and one week after CJC-1295 administration, using two-dimensional gel electrophoresis to examine serum-protein patterns. This was exploratory biomarker research, not an efficacy trial.

The analysis detected 192 protein spots; 97 appeared in all subjects. Five of those 97 showed significant changes. Spots identified as an apolipoprotein A1 isoform and a transthyretin isoform decreased. Spots identified as beta-hemoglobin, a C-terminal albumin fragment, and a mixture containing an immunoglobulin fragment and another albumin fragment increased.

Those identifications describe spots in an assay, not necessarily changes in the total amount or clinical function of each named protein. The mixed spot is especially important to read cautiously: its change cannot be assigned to just one of its identified components on the basis of the reported result. The study proposed potential biomarkers for further investigation. It did not validate those spots as indicators of clinical benefit or establish that another research material would produce the same profile.

Evidence comparison: study material, catalog listing, and unsupported inference

How to read the comparison

The objects below are different kinds of evidence. Human studies report observations in defined participants; catalog entries report listing information; a serum-protein analysis reports exploratory assay findings. Reading across a row shows both what is documented and where an inference must stop. Reading down a column should not turn unlike objects into equivalent tests of the same batch.

Where equivalence stops

The table does not rank products or imply that one listing has undergone the testing described in another row. Its purpose is to keep study identity, catalog identity, and observed endpoints separate. The long-acting human findings concern the material examined in those publications. The with-DAC listing supplies a related name, not proof of a match; the without-DAC listing supplies a different name, not a tested comparison group.

Likewise, the 2009 protein observations cannot repair a missing product-identity link. They add a question about possible serum biomarkers under the conditions studied. They do not establish a clinical endpoint or verify either catalog entry. If an inference crosses from a paper to a present-day batch, the documentation supporting that crossing must be evaluated separately rather than assumed from familiar wording.

Research documentation and unresolved questions

Identity and batch-documentation checklist

For a laboratory reader, the first documentation question is simple: What material is the record actually describing? Record the exact catalog name and listed quantity, then keep those details separate from any published study description. Look for documentation tied to the particular batch rather than relying on a general product title. A statement about the design of studied CJC-1295 is not, without a batch-specific analytical link, a statement about a catalog vial.

Next, ask whether the available documentation addresses the molecular identity relevant to the planned comparison, including the feature denoted by DAC. Ask what analytical evidence supports the identification and which batch it covers. These are questions to resolve, not assertions that a particular test was performed or that either BioPharma item has a specified purity, composition, or performance.

Finally, record which claim is being evaluated. Is it the identity of a material, its analytical detection, a hormone measurement in human participants, or a proposed serum biomarker? Timms and colleagues’ LC-MS/MS work concerns confirmation in equine plasma; it illustrates an analytical context but supplies neither BioPharma batch documentation nor human efficacy evidence. Keeping a claim beside its source makes gaps visible instead of filling them with a product name.

Unresolved questions remain even after the early studies are read closely. The cited human work involved healthy adults and specific observation periods. It does not establish long-term outcomes or show whether either current catalog item is identical to the studied analog. The without-DAC listing, in particular, cannot inherit the albumin-binding description or reported half-life merely because it shares the CJC-1295 name.

Why biomarker changes do not prove consumer benefits

GH and IGF-I are measured biological endpoints. An increase tells readers what changed in a test, not whether a participant experienced a meaningful clinical benefit. A pharmacokinetic estimate answers a different question about the studied material’s observed time course. Preserved GH pulsatility answers another question about a measured secretion pattern. None is interchangeable with an outcome the studies did not demonstrate.

The exploratory protein work adds a further layer of uncertainty. Five changing spots among those shared across the study participants may be useful leads for biomarker investigation, but their mechanisms and clinical interpretation require more work. A protein spot is not a validated consumer outcome. Nor does a small, defined group of healthy young men establish the same response in all populations or for every similarly named material.

For evidence-aware purchasing and reading, the practical conclusion is restrained: use publications to understand what researchers measured, and use appropriately matched documentation to assess what a particular research material is. Do not use one evidence layer to stand in for the other. This article makes no claim about the clinical utility, safety, or study equivalence of a BioPharma catalog item.

Key Terms and Definitions

GHRH

Growth hormone-releasing hormone; the pathway referenced when the studied CJC-1295 is called a GHRH analog. It is distinct from the ghrelin-receptor context discussed for ipamorelin.

DAC

Drug affinity complex terminology associated with the albumin-binding design described for the studied long-acting analog; the letters on a catalog label do not verify a batch.

Albumin binding

Association of the studied analog with endogenous albumin, described in the literature as part of its long-acting design.

IGF-I

Insulin-like growth factor I, a measured hormone endpoint in the cited human studies, not a stand-alone measure of clinical benefit.

Trough GH

The lower measured GH level between secretory peaks; it increased in the cited pulsatility study.

Pharmacokinetics

Measurements describing the studied compound’s concentration and time course, including its reported half-life.

2D gel electrophoresis

Two-dimensional gel electrophoresis, the method used to separate serum proteins into spots in the exploratory biomarker study.

Biomarker

A measurable biological feature investigated as a possible indicator; an exploratory candidate is not necessarily a validated clinical measure.

Catalog identity

The name and listing information used to identify an item in a catalog, distinct from analytical evidence about a particular batch.

Frequently Asked Questions About CJC-1295 Research

What is CJC-1295 with DAC?

In the early human research discussed here, CJC-1295 is a synthetic, long-acting analog of growth hormone-releasing hormone. The DAC terminology refers to the albumin-binding design associated with that studied analog. This description helps identify the subject of the publications. It does not independently verify the molecular identity, composition, or performance of a catalog item bearing the with-DAC name.

What does DAC refer to?

DAC refers to drug affinity complex terminology. In this research context, it identifies a design described as allowing the studied analog to bind endogenous albumin, contributing to its extended presence in circulation. It is a useful clue when reading a study or catalog name, but the letters alone are not laboratory confirmation that a particular batch has the described identity or properties.

Why is albumin binding important in this research?

The published long-acting analog is described as binding albumin, which helps explain why researchers observed it over an extended period. That feature provides context for the reported pharmacokinetic findings and sustained hormone measurements. It is not a use recommendation. Nor can the description be assigned to a separately listed material without evidence that its identity matches the material studied.

Are with-DAC and without-DAC catalog products interchangeable?

Interchangeability cannot be concluded from these listings. BioPharma uses separate with-DAC and without-DAC catalog names, but a name is not batch-level analytical evidence. The long-acting human findings cannot automatically be transferred to the without-DAC entry, and the available studies do not provide a head-to-head comparison of the two catalog items. Identity and evidence applicability must be considered separately.

What did the early randomized trials measure?

The early randomized, placebo-controlled trials studied healthy adults and measured GH and IGF-I concentrations along with pharmacokinetic parameters for the studied CJC-1295. The reported changes describe hormone responses and the observed time course under research conditions. They do not demonstrate a consumer benefit, establish results for a present-day catalog batch, or provide instructions for using research materials.

Do GH and IGF-I changes demonstrate a clinical benefit?

No. GH and IGF-I changes show differences in measured biological endpoints, not whether an unmeasured clinical outcome improved. The studies involved defined healthy-adult populations and limited observation periods. Their results cannot be generalized into claims of long-term safety, treatment effectiveness, or equivalent effects from any similarly named catalog material. Each of those claims would require evidence addressing that specific question.

What did the 2009 serum-protein study examine?

Researchers examined serum samples from 11 healthy young adult men before and one week after CJC-1295 administration. Using two-dimensional gel electrophoresis, they identified five shared protein spots with significant changes, including spots associated with albumin fragments and other proteins. This was exploratory biomarker work: the observed spots were not validated as measures of clinical benefit or as predictions for a catalog product.

Is ipamorelin the same research compound?

No. Ipamorelin is a separate research compound discussed in a different pathway context involving the ghrelin receptor. A related introduction can help readers distinguish terminology, but it does not make the compounds equivalent. Findings about the studied GHRH analog should not be transferred to ipamorelin, or the reverse, simply because both appear in discussions of GH-related research.

Does a product name verify identity or purity?

No. A catalog name and listed quantity tell readers how an item is presented, not what independent analysis has established about a specific batch. Identity and purity are separate analytical questions. Likewise, a published study of a named analog cannot serve as a certificate for a current catalog item. Any proposed link between the study material and a batch requires appropriately matched documentation.

Does this research provide a dosing or human-use protocol?

No. The publications report historical research conditions and measurements; this article does not convert them into directions for a catalog material. It provides no preparation, route, administration, treatment, or dosing guidance. BioPharma research materials are for research and laboratory use only, not human or veterinary use. Questions about what a study measured should remain separate from instructions for using a product.

Sources

• Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295… J Clin Endocrinol Metab. 2006. PMID 16352683. Randomized controlled trials.
• Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295… J Clin Endocrinol Metab. 2006. PMID 17018654. Clinical trial.
• Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295… serum protein profile changes Growth Horm IGF Res. 2009. PMID 19386527 (full text PMC2787983).
• Timms M, et al. A method for confirming CJC-1295 in equine plasma samples by LC-MS/MS Drug Test Anal. 2019. PMID 30938069. Analytical validation study.

Explore BioPharma Research Materials

Qualified laboratory readers can consult the BioPharma CJC-1295 with DAC 5mg research material listing or browse the research peptides category for catalog context. These pages are listing references, not evidence that an item matches the material in a human study.

For related terminology, see the ipamorelin research introduction. Ipamorelin and the studied CJC-1295 analog are different compounds associated with different pathway contexts; evidence must not be transferred between them.

Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice. BioPharma provides no dosing, preparation, route, administration, treatment, efficacy, or safety instructions.